LAB150 is a focused drug development program which invests in target-driven discovery projects that supports TIAP’s research commercialization mission. LAB150 is co-managed by TIAP and strategic industry partners, Amgen and Evotec SE, creating an environment where entrepreneurs can benefit from a deep technical and clinical knowledge base.
LAB150 de-risks projects and creates value by advancing therapeutic candidates from discovery to preclinical validation. Completing this program of set development milestones program readies projects for successful venture formation and venture capital investment.
- Target Identification and Validation
- Screening and Hit Identification
- Testing Novel Therapeutics in In-Vivo Models
- Drug Metabolism and Pharmacokinetics
- Medicinal Chemistry
- Proteomics and Metabolomics
Only life science projects from our Members already in the TIAP pipeline are eligible for development through LAB150. After extensive technical, market and intellectual property due diligence, the researcher is invited to present the technology to the LAB150 Joint Steering Committee. The JSC makes the final admission decision.
Members of the Joint Steering Committee:
Margaret Chu-Moyer, VP Research, Amgen
Paul Hughes, Executive Director Oncology, Amgen
Daniel Jun Martinez, Medical Director, Amgen
Thomas Hanke, EVP, Head of Academic Partnerships, Evotec
Mark Slack, SVP Partnerships, Evotec
Parimal Nathwani, President & CEO, TIAP
Tanya Borsuk, Independent, on behalf of TIAP
Contact LAB150:
pgoldbach@tiap.ca – attention Phil Goldbach
LAB150 Strategic Partners
